中国ST段抬高的急性心肌梗死临床特征及治疗现状

发布时间：2018-07-25 08:37

【摘要】：目的分析中国ST段抬高心肌梗死(STEMI)的基线特征及治疗现状。方法作为国际多中心试验CREATE研究的一部分,2001年7月至2004年7月入选症状出现12小时内的STEMI病人,分析基线特征及治疗现状。结果中国274中心入选7510例病人,STEMI病人中0.7%为新出现的左束支传导阻滞。平均年龄62.7岁。11.5%接受PCI治疗,溶栓治疗52.5%,冠状动旁路移植术0.1%,总体接受再灌注治疗(包括溶栓及直接PCI)为62.4%。其他药物治疗情况与以往的登记研究相似。7天的死亡、卒中、再梗死联合终点为10.3%。30天总死亡率为11.1%。结论与全组急性冠脉事件登记研究相比较;中国STEMI病人的发病年龄与之相类似,伴发高血压者较多,有糖尿病史者稍少,接受再灌注率相似。但在再灌注治疗及药物治疗上还存在进一步改善的空间。
[Abstract]:Objective to analyze the baseline features and treatment status of St segment elevation myocardial infarction (St segment elevation) (STEMI) in China. Methods as part of the international multi-center CREATE study, STEMI patients who had symptoms within 12 hours from July 2001 to July 2004 were selected to analyze the baseline characteristics and treatment status. Results 0.7% of 7510 patients with STEMI in China 274 Center were newly developed left bundle branch block. The average age was 62.7 years. The mean age was 52.5 for thrombolytic therapy, 0.1 for coronary artery bypass grafting, and 62.4 for total reperfusion therapy (including thrombolytic therapy and direct PCI). Other drug treatments were similar to previous registered studies in mortality of 7 days, stroke, reinfarction combined end point was 10.3 and total mortality of 30 days was 11.1. Conclusion compared with the whole group of patients with acute coronary events, the age of onset of STEMI in China is similar, the incidence of hypertension is more, the history of diabetes is less, and the rate of reperfusion is similar. However, there is room for further improvement in reperfusion therapy and drug therapy.
【作者单位】：中国医学科学院中国协和医科大学阜外心血管病医院急症抢救科中国医学科学院中国协和医科大学阜外心血管病医院急症抢救科中国医学科学院中国协和医科大学阜外心血管病医院急症抢救科中国医学科学院中国协和医科大学阜外心血管病医院急症抢救科中国医学科学院中国协和医科大学阜外心血管病医院急症抢救科中国医学科学院中国协和医科大学阜外心血管病医院急症抢救科中国医学科学院中国协和医科大学阜外心血管病医院急症抢救科
【分类号】：R542.22

【参考文献】